Open Access

REVIEW

Current and future therapies for abnormal early embryogenesis with assisted reproductive technology

XIAOXIA WANG^1,#, ZHONGYUAN YAO^1,2,#, DI LIU¹, CHUNHONG YU^3,*, HUI LI^1,3,*

1 Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, 410000, China
2 Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, 410078, China
3 Hunan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, 410000, China

* Corresponding Authors: CHUNHONG YU. Email: ; HUI LI. Email:
# The two authors contributed equally as first author

(This article belongs to the Special Issue: Reproductive Health and Embryonic Development)

BIOCELL 2022, 46(8), 1803-1806. https://doi.org/10.32604/biocell.2022.019731

Received 11 October 2021; Accepted 21 December 2021; Issue published 22 April 2022

Abstract

Each stage of embryonic development, including normal gamete maturation, fertilization, zygotic genome activation, and cleavage, is crucial for human reproduction. Early embryo arrest is a common phenomenon. It is estimated that about 40%–70% of human embryos are arrested at early developmental stages. However, the exact mechanism remains largely uncertain. Embryos can be investigated in vitro by way of the development of in vitro fertilization/intracytoplasmic sperm injection. In addition to iatrogenic factors related to abnormal oocyte/embryo development, multiple gene mutations have been found to be involved in such phenotypes. Based on the knowledge of known etiological factors, several therapies are proposed to improve clinical outcomes. Here, we shed light on current and potential therapies for treating these conditions through reviewing articles and combining with our clinical and research experience.

---

Keywords

---